1-3 of 3
Josephine Kahn
Close
Sort by
Journal Articles

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Peter G. Miller, Adam S. Sperling, Christina Mayerhofer, Marie E. McConkey, Jana M. Ellegast, Carmen Da Silva, Drew N. Cohen, Chuqi Wang, Azeem Sharda, Ni Yan, Subha Saha, Cameron Schluter, Ilexa Schechter, Mikołaj Słabicki, Brittany Sandoval, Josephine Kahn, Steffen Boettcher, Christopher J. Gibson, David T. Scadden, Kimberly Stegmaier, Shruti Bhatt, R. Coleman Lindsley, Benjamin L. Ebert
Journal: Blood
Blood (2023) 142 (24): 2079–2091.
https://doi.org/10.1182/blood.2023020331
Published: 2023
Includes: Supplemental data
Journal Articles

PPM1D Truncating Mutations Confer Chemotherapy Resistance in Hematopoietic Stem Cells, Which Is Reversible By PPM1D Inhibition

Josephine Kahn, MD, Alexander J. Silver, B.S., Philipp Mertins, PhD, Steven Carr, PhD, Siddhartha Jaiswal, MD PhD, Benjamin L. Ebert, MD PhD
Journal: Blood
Blood (2016) 128 (22): 740.
https://doi.org/10.1182/blood.V128.22.740.740
Published: 2016
Journal Articles

SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response

Brenton G. Mar, MDPhD, Josephine Kahn, MD MSc, Rebecca L Zon, BA, Peter V Grauman, BS, Kevin Boettger, BS, Scott Haihua Chu, PhD, Scott A. Armstrong, MD PhD, Benjamin L. Ebert, MD
Journal: Blood
Blood (2015) 126 (23): 2626.
https://doi.org/10.1182/blood.V126.23.2626.2626
Published: 2015